MRL, Merck & Co., Inc., Rahway, NJ, USA.
Nat Commun. 2024 Sep 9;15(1):7877. doi: 10.1038/s41467-024-51692-0.
We report bio-structural, bio-chemical and bio-physical evidence demonstrating how small molecules can bind to both wild-type and mutant IDH1, but only inhibit the enzymatic activity of the mutant isoform. Enabled through x-ray crystallography, we characterized a series of small molecule inhibitors that bound to mutant IDH1 differently than the marketed inhibitor Ivosidenib, for which we have determined the x-ray crystal structure. Across the industry several mutant IDH1 inhibitor chemotypes bind to this allosteric IDH1 pocket and selectively inhibit the mutant enzyme. Detailed characterization by a variety of biophysical techniques and NMR studies led us to propose how compounds binding in the allosteric IDH1 R132H pocket inhibit the production of 2-Hydroxy glutarate.
我们报告了生物结构、生物化学和生物物理证据,证明了小分子如何能够与野生型和突变型 IDH1 结合,但仅抑制突变体同工酶的酶活性。通过 X 射线晶体学,我们对一系列小分子抑制剂进行了表征,这些抑制剂与突变型 IDH1 的结合方式与市售抑制剂ivosidenib 不同,我们已经确定了后者的 X 射线晶体结构。在整个行业中,有几种突变型 IDH1 抑制剂化学型与这个变构 IDH1 口袋结合,并选择性地抑制突变酶。通过各种生物物理技术和 NMR 研究的详细表征,我们提出了化合物结合在变构 IDH1 R132H 口袋中如何抑制 2-羟基戊二酸的产生。